EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

GLP‐1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations

Mohanad A Alkuwaiti iD, Faisal A Al-Harbi iD, Ahmed K Alsaif, Ziyad M AlSughayyir, Rayan Saleh Alsaud, Mohammed N Aljabr, Ahmad K Alanazi, Ahmad A Alosaily, Abdulrhman K Alabdulqader, Hamza Almusabeh, Rayyan F Altemani, Ahmed Y Azzam iD

Journal of Gastroenterology and Hepatology · 2026

DOI: 10.1111/jgh.70589 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Mohanad A Alkuwaiti und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) have demonstrated cardiovascular and metabolic benefits individually; however, the comparative effectiveness of combination therapy versus monotherapy in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) remains incompletely characterized.

Methods

We conducted three pairwise target trial emulations using the TriNetX Research Network. Adults with MASLD and T2DM initiating GLP‐1 RA plus SGLT2i combination therapy, GLP‐1 RA monotherapy, or SGLT2i monotherapy were identified. Primary outcomes were all‐cause mortality, major adverse cardiovascular events (MACE), and composite liver outcomes. Propensity score matching (PSM) (1:1) was performed for each pairwise comparison. Cox proportional hazards regression with Bayesian hierarchical bias‐effect (BHBE) correction was utilized to address residual confounding.

Results

Following PSM, 42423 combination versus 42 423 GLP‐1 RA, 40349 combination versus 40 349 SGLT2i, and 51 826 GLP‐1 RA versus 51 826 SGLT2i patients were analyzed. Combination therapy significantly reduced all‐cause mortality versus SGLT2i monotherapy (hazard ratio [HR] 0.522, 95% confidence interval [CI] 0.488–0.559), with probable benefit after bias correction (corrected HR 0.655, posterior probability 92.4%; credible interval includes the null). Combination therapy demonstrated increased MACE risk versus GLP‐1 RA (HR 1.106, 95% CI 1.045–1.170), remaining significant after correction (corrected HR 1.111). Composite liver outcomes favored combination therapy versus SGLT2i (corrected HR 0.907, probability of benefit 81.9%).

Conclusions

GLP‐1 RA and SGLT2i combination therapy significantly reduced mortality and liver outcomes versus SGLT2i monotherapy in MASLD with T2DM; however, increased MACE risk versus GLP‐1 RA monotherapy warrants consideration in management decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsFatty LiverHumansDrug Therapy, CombinationFemaleTreatment OutcomeMaleMiddle AgedAgedCardiovascular Diseases

Stichwörter der Autor:innen

GLP‐1 RAMASLDSGLT2 inhibitorscardiometabolic outcomesdiabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
  • College of Medicine, Qassim University, Qassim, Saudi Arabia.
  • College of Medicine, Al-Rayan Colleges, Medinah, Saudi Arabia.
  • Department of Internal Medicine, College of Medicine, King Faisal University, Al-Ahsa, Saudi Arabia.
  • Department of Internal Medicine, West Virginia University School of Medicine, Morgantown, West Virginia, USA.
  • Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.

ORCID-Profile: Mohanad A Alkuwaiti, Faisal A Al-Harbi, Ahmed Y Azzam

Zitieren

APA

Alkuwaiti, M. A., Al-Harbi, F. A., Alsaif, A. K., AlSughayyir, Z. M., Alsaud, R. S., Aljabr, M. N., Alanazi, A. K., Alosaily, A. A., Alabdulqader, A. K., Almusabeh, H., Altemani, R. F., & Azzam, A. Y. (2026). GLP‐1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70589

Vancouver

Alkuwaiti MA, Al-Harbi FA, Alsaif AK, AlSughayyir ZM, Alsaud RS, Aljabr MN, et al. GLP‐1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70589

BibTeX
@article{Alkuwaiti2026,
  author = {Alkuwaiti, Mohanad A and Al-Harbi, Faisal A and Alsaif, Ahmed K and AlSughayyir, Ziyad M and Alsaud, Rayan Saleh and Aljabr, Mohammed N and Alanazi, Ahmad K and Alosaily, Ahmad A and Alabdulqader, Abdulrhman K and Almusabeh, Hamza and Altemani, Rayyan F and Azzam, Ahmed Y},
  title = {GLP‐1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  doi = {10.1111/jgh.70589}
}
Kostenlos starten →